Renal Cancer - Results from #1000

Influence of metabolic syndrome on survival of patients with localized renal clear cell carcinoma: A retrospective cohort study in China. March 28, 2023

Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma. March 27, 2023

Radical versus partial nephrectomy for T1 non-clear cell renal cell carcinoma. March 27, 2023

Necessity of prophylactic drainage tube in retroperitoneal laparoscopic nephroureterectomy with open distal ureterectomy: A matched-pair analysis. March 27, 2023

The Changing Landscape of Immunotherapy for Advanced Renal Cancer. March 24, 2023

The Promise of Neoadjuvant and Adjuvant Therapies for Renal Cancer. March 24, 2023

Radiation Therapy in the Treatment of Localized and Advanced Renal Cancer. March 24, 2023

Integrating Surgery in the Multidisciplinary Care of Advanced Renal Cell Carcinoma. March 24, 2023

Surgical Management of Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus. March 24, 2023

Feasibility of biology-guided radiotherapy for metastatic renal cell carcinoma driven by PSMA PET imaging. March 23, 2023

Differential Prognostic Value of Extrarenal Involvement in Patients With Non-Metastatic Renal Cell Cancer. March 23, 2023

Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment. March 22, 2023

Renal Mass Biopsy Mandate Is Associated with a Change in Treatment Decisions. March 22, 2023

Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma-A network meta-analysis. Focus on cabozantinib combined with nivolumab. March 22, 2023

Prevalence of germline mutations in cancer susceptibility genes in Chinese patients with renal cell carcinoma. March 20, 2023

Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal Cancer. March 20, 2023

Impact of Overweight and Obesity on U.S. Renal Cell Carcinoma Incidence Trends (1995-2018). March 20, 2023

Risks and benefits of partial nephrectomy with limited or without ischemia time. March 20, 2023

Cytoreductive partial and radical nephrectomies provide equivalent oncologic outcomes in T1-2M1 renal cell carcinoma. March 17, 2023

Baseline and Dynamic Changes in Hemoglobin Levels Predict Treatment Response and Prognosis in Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study. March 17, 2023

Page 51 of 455